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SUMMARY
A 55-year-old man with a history of chronic lymphocytic
leukaemia presented with diffuse skin lesions that began
1 week after starting a new chemotherapy regimen with
bendamustine and rituximab. The lesions appeared as
erythematous papules that were neither itchy nor tender,
and did not blanch with pressure. Initially, they began
on his scalp and ﬂanks and, over the next few days,
spread diffusely throughout his body, becoming darker in
colour. Skin biopsy showed atypical clonal B-cell
proliferation in a perivascular, periadnexal and dermal
band-like distribution, which was further characterised by
immunohistochemical evaluation. These ﬁndings were
suggestive of leukaemia cutis and consistent with the
patient’s chronic lymphocytic leukaemia, which was
previously conﬁrmed by bone marrow biopsy. The
bendamustine was stopped and the patient’s
chemotherapy regimen was switched to ﬂudarabine,
cyclophosphamide and rituximab. Shortly thereafter, the
leukaemia cutis regressed signiﬁcantly.

BACKGROUND
Leukaemia cutis is an uncommon skin manifestation of various forms of leukaemia, and occurs
when neoplastic leucocytes inﬁltrate the dermis,
resulting in clinically visible skin lesions.1 It usually
portends a poor prognosis, as 90% of patients with
this condition tend to have additional sites of extramedullary involvement.2 While only a few case
reports have previously reported leukaemia cutis
occurring following chemotherapy, none, to the
best of our knowledge, have reported it in relation
to bendamustine. We report a rare case of a
55-year-old man with atypical chronic lymphocytic
leukaemia who developed leukaemia cutis after
starting bendamustine chemotherapy.

CASE PRESENTATION
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A 55-year-old man with atypical chronic lymphocytic leukaemia, diagnosed in 2001 in Nigeria, presented with diffuse skin lesions that started a week
after his ﬁrst cycle of bendamustine and rituximab
chemotherapy.
The patient began therapy for his chronic
lymphocytic leukaemia on arrival to the USA in
2008, with one cycle of cyclophosphamide, vincristine and prednisone. Bone marrow biopsy and peripheral blood smear at the time revealed extensive
inﬁltration with lymphocytes, positive for CD5,
CD20 and CD23, and negative for CD38, t(11,14)
and cyclin D1. In 2009, the patient completed four
cycles of ﬂudarabine, cyclophosphamide and rituximab (FCR), with clinical improvement. He was lost

to follow-up for 2 years and presented again in
2013, with radiographic evidence of disease progression. At that time, he was started on his ﬁrst
cycle of bendamustine–rituximab. The regimen signiﬁcantly reduced tumour burden. The patient’s
complete blood count on the day prior to starting
the cycle of bendamustine–rituximab revealed a
white cell count of 191 000/mL; haemoglobin of
9.1 g/dL and platelet count of 35 000/mL. After the
ﬁrst cycle, complete blood count revealed reduction
in all cell lines as follows: white cell count of
89 600/mL; haemoglobin of 7.9 g/dL and platelet
count of 17 000/mL.
A week after starting this new chemotherapy
regimen, the patient developed diffuse skin lesions
and presented to the hospital. The lesions appeared
as erythematous papules that were non-tender and
non-pruritic, and did not blanch with pressure.
Initially, they began on his scalp and ﬂanks and,
over the next few days, spread diffusely throughout
his body, becoming darker in colour. There were
no associated constitutional symptoms such as
fevers, chills, night sweats or weight loss, and no
arthralgia.
Physical examination revealed erythematous and
violaceous indurated nodules and papules concentrated on the back, scalp, face, chest, abdomen,
bilateral arms and bilateral legs (ﬁgures 1 and 2).
The distal arms and legs were spared. A large, nontender lymph node was palpated in the left axilla.
The remainder of the examination was
unremarkable.

INVESTIGATIONS
A complete blood count and comprehensive metabolic panel revealed a white cell count of 87
900/mm3, haemoglobin of 8.4 g/dL, platelet count of
36 000/mm3 and creatinine level of 1.32 mg/dL. Liver
function tests were unremarkable. A CT of the chest,
abdomen and pelvis, performed a week prior, had
revealed diffuse lymph node enlargement, including
periportal, mesenteric, portacaval, periaortic, pericaval, bilateral common iliac, external iliac, obturator
and inguinal lymph nodes, consistent with worsening
chronic lymphocytic leukaemia. An ultrasound of the
left axilla revealed a 4.6×3.7×3.8 cm heterogeneous,
hypoechoic mass with no internal vascular ﬂow, suggestive of an enlarged lymph node.
A skin punch biopsy of several skin lesions was
obtained from the right thigh. Histopathology
revealed atypical clonal B-cell proliferation in a
perivascular, periadnexal and dermal band-like distribution. Clonality was deﬁned by a clonal IgH
gene rearrangement by PCR. The skin biopsy
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Figure 1 Skin lesions, day 2 after onset. Erythematous nodules and
papules on the skin ( photograph taken by the patient prior to
hospitalisation).

revealed dense inﬁltrates of purely B cells with clonality as
deﬁned above, thus we do not suspect the tissue lesions were
simply reactive in nature but, rather, believe they were neoplastic. Further immunohistochemical evaluation revealed positive
reactivity for CD20, CD3 and BCL-2, and negative reactivity
for CD5, CD23, cyclin D1, BCL-6 and CD10 (ﬁgures 3–8).
These ﬁndings were consistent with leukaemia cutis and compatible with the diagnosis of atypical lymphocytic leukaemia, which
was previously conﬁrmed by bone marrow biopsy.
The patient’s prior bone marrow biopsy had revealed
co-expression of CD5 and CD23, which were only dimly
expressed; however, these were not detected on the cutaneous
inﬁltrates. Several reasons may explain this aberration. First, the
skin biopsy was assessed with histology and immunohistochemistry only. Flow cytometry, a more sensitive technique that can
detect dimly expressed receptors, was not performed due to
scant tissue sample. Second, given the duration of time between
bone marrow and skin biopsies, it is possible that phenotypic
variation, as a result of genotypic evolution over the life time of
the cancer cell line, may have taken place. Third, phenotypic
evolution in cancer cells postchemotherapy has been described
previously and may have occurred. These three possible explanations may account for the noted aberration.
To determine clonality, IgH gene rearrangement testing was
carried out on the skin biopsy. The cell population was found to
be monoclonal. However, at our institution, we do not routinely
perform IgH gene rearrangements on bone marrow biopsies
but, rather, we assess for clonality by ﬂow cytometry. However,
since ﬂow cytometry is not usually performed on skin specimens
due to the minute nature of the biopsies, in these instances,
PCR methodology with IgH gene rearrangement is performed
at our institution, because it can be performed on formalin
ﬁxed tissues and can be carried out on relatively scant
specimens.

TREATMENT
The bendamustine was stopped and the patient’s chemotherapy
regimen was switched to FCR. Shortly thereafter, the leukaemia
cutis regressed signiﬁcantly.

OUTCOME AND FOLLOW-UP
The patient completed two cycles of FCR. He did not reach
remission. He was lost to follow-up after the two cycles and
later died due to infectious complications before being
re-staged.

Figure 2 Skin lesions regressing after chemotherapy was switched to
ﬂudarabine, cyclophosphamide and rituximab regimen. Day 18 after
onset.
2

Figure 3 Skin biopsy. Low-power examination (×10) of H&E stains
showing perivascular and periadnexal lymphocytic inﬁltrates in the
dermis.
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Figure 4 Skin biopsy. High-power examination (×20) showing similar
ﬁndings in more detail.

Figure 6
CD20.

DISCUSSION
Leukaemia cutis is a term used to describe inﬁltration of leucaemic white cell counts or their precursors into the skin, resulting
in clinically apparent skin lesions. This condition can manifest
in various leukaemia types, including chronic lymphocytic
leukaemia, acute lymphoblastic leukaemia, acute myelogenous
leukaemia and chronic myelogenous leukaemia. Leukaemia cutis
is relatively rare, affecting only about 3% of patients diagnosed
with leukaemia. Interestingly, it can manifest as the initial clinical presentation of leukaemia in about 7% of these cases, prior
to any evidence of malignant leucocytes in the blood.3 This is
dubbed aleucaemic leukaemia cutis. Hence, accurate diagnosis
in such cases can have tremendous prognostic signiﬁcance.
Furthermore, leukaemia cutis can be a manifestation of a relapse
of previously treated systemic leukaemia. A diagnosis of leukaemia cutis in the setting of acute leukaemia generally portends a
poor prognosis and strongly correlates with additional sites of
extramedullary involvement. Treating this condition can be a
challenge, as it might be resistant to chemotherapy.4
The gross appearance of leukaemia cutis may vary. It can
present as ﬁrm papules, diffuse eczema, annular erythema,
purpura, petechiae or blisters that are usually asymptomatic.5 6
Although leukaemia cutis may be suspected from the patient’s
history and the cutaneous appearance, a skin biopsy is necessary
to conﬁrm the diagnosis. It classically reveals a diffuse

inﬁltration of malignant leucocytes in the dermis. Different patterns can be observed on histology, depending on the primary
leukaemia. Additional immunohistochemistry may reveal the
speciﬁc cell type involved. It is sometimes very difﬁcult to diagnose leukaemia cutis. Managing leukaemia cutis consists of
treating the underlying malignancy. Generally, agents such as
rituximab, cyclophosphamide and cladribine have been shown
to be effective.7 8
It is very unusual for leukaemia cutis to develop as a response
to chemotherapy, which is used for the treatment of leukaemia.9
A review of the literature reveals only a few case reports documenting this phenomenon, with cyclophosphamide as the presumed culprit. One report describes a middle-aged woman who
developed leukaemia cutis after completing her fourth cycle of
cyclophosphamide and doxorubicin for treatment of inﬁltrating
ductal carcinoma of the breast.10 Another report describes an
elderly woman who developed leukaemia cutis after completing
her third cycle of cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone for treatment of blasticplasmacytoid
dendritic cell neoplasm.11 Other reports describe various skin
manifestations, other than leukaemia cutis, following initiation
of bendamustine.12–14 However, skin biopsy ﬁndings in such
cases show simple inﬂammation rather than leucaemic inﬁltration. A case of leukaemia cutis in association with activation of
varicella-zoster virus has also been described.15

Figure 5 Immunohistochemical staining. Tumour cells positive for
BCL-2.

Figure 7
CD5.
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rapidly with cessation of this chemotherapeutic agent strongly
suggests that the leukaemia cutis was related to and likely triggered by bendamustine.
To the best of our knowledge, there are no prior reported
cases of leukaemia cutis developing following initiation of bendamustine. This case illustrates the necessity of maintaining a
high level of vigilance for the detection of leukaemia cutis in
patients presenting with characteristic diffuse skin lesions, in the
setting of history of leukaemia. It also highlights the importance
of keeping this diagnosis high in the differential of leucaemic
patients presenting with diffuse non-pruritic skin involvement
following treatment with bendamustine or other chemotherapeutic agents.

Figure 8 Immunohistochemical staining. Tumour cells negative for
CD3.
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Studies have demonstrated that alteration in leucaemic cell
receptors can occur over time as a response to chemotherapy or
as part of the natural evolution of the neoplastic cells. These
receptor changes may lead to chemotherapy resistance as well as
progression of disease in leucaemic patients.16 17 While different
receptors were noted on histopathochemistry testing for cutaneous versus bone marrow biopsy lymphocytes in our patient, this
may have been due to phenotypic alteration of the receptors
over time or lack of detection of dimly expressed receptors with
use of immunohistochemistry testing instead of ﬂow cytometry.
Our leucaemic patient did not have any skin lesions before starting bendamustine. The observation that leukaemia cutis developed immediately after starting bendamustine and regressed
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